1. Show article details.

    Hemp and CBD Arise as Alternatives to the Tobacco Industry

    PR Newswire – 9:00 AM ET 08/03/2020

    NEW YORK, Aug. 3, 2020 The tobacco industry is a major market, and in some aspects, it is evolving to adapt to a new demographic. Next generation products, such as new forms of e-cigarettes and heated tobacco products, are rising in popularity in the market. The tobacco industry is also influenced by the increasing consumption of CBD and hemp products.

  2. Show article details.

    BAT first-half beats expectations on 'resilient' U.S. demand

    Reuters – 4:30 AM ET 07/31/2020

    * E-cigarette sales rise 75% in US. * US industry volumes revised to down 2.5% * Maintains FY forecast for revenue and earnings growth. * Shares up 1.6% By Siddharth Cavale. British American Tobacco (BTI) reported stronger-than-expected first-half profit on Friday, as consumers bought more vaping products and higher-priced cigarettes in the United States, its biggest market.

  3. Show article details.

    CBD Could Help Smokers Move on From Tobacco

    PR Newswire – 9:00 AM ET 07/27/2020

    NEW YORK, July 27, 2020  In recent years, CBD and hemp-derived products have seen a massive surge in popularity.

  4. Show article details.

    The Importance of Science-Based Decision-Making Highlighted in Latest Issue of Philip Morris International’s Scientific Update

    Business Wire – 10:48 AM ET 07/23/2020

    - Science-based decision-making requires that researchers recognize and address their biases, use validated scientific methods, and publish their work transparently. - As the market for heated tobacco products expands, the availability of accurate and non-misleading information about these products is vital.

  5. Show article details.

    BRIEF-Philip Morris International Says Qtrly Net Revenues $6.65 Billion Versus About $7.70 Billion

    Reuters – 8:23 AM ET 07/21/2020

    Philip Morris International Inc (PM): * QTRLY NET REVENUES $6.65 BILLION VERSUS ABOUT $7.70 BILLION.

  6. Show article details.

    BRIEF-Philip Morris International Inc Reports 2020 Second-Quarter Reported Diluted EPS Of $1.25 Versus $1.49 In 2019

    Reuters – 7:23 AM ET 07/21/2020

    Philip Morris International Inc (PM): * . REPORTS 2020 SECOND-QUARTER REPORTED DILUTED EPS OF $1.25 VERSUS $1.49 IN 2019, REFLECTING CURRENCY-NEUTRAL ADJUSTED DILUTED EPS DECLINE OF 7.5% * PROVIDES 2020 FULL-YEAR REPORTED DILUTED EPS FORECAST OF $4.84 TO $4.99. * PROVIDES 2020 FULL-YEAR ADJUSTED DILUTED EPS FORECAST OF $4.92 TO $5.07. * QTRLY ADJUSTED DILUTED EPS OF $1.29, DOWN BY 11.6%; DOWN BY 7.5...

  7. Show article details.

    Philip Morris International Inc. Reports 2020 Second-Quarter Reported Diluted EPS of $1.25 Versus $1.49 in 2019, Reflecting Currency-Neutral Adjusted Diluted EPS Decline of 7.5%

    Business Wire – 6:59 AM ET 07/21/2020

    Provides 2020 Full-Year Reported Diluted EPS Forecast of $4.84 to $4.99, or Adjusted Diluted EPS of $4.92 to $5.07, Reflecting Like-for-Like Currency-Neutral Growth of Approximately 2% to 5% Regulatory News: Philip Morris International Inc. (PM) today announces its 2020 second-quarter results.

  8. Show article details.

    US STOCKS-Futures climb on IBM earnings report, stimulus hopes

    Reuters – 6:34 AM ET 07/21/2020

    * Futures up: Dow 0.60%, S&P 0.69%, Nasdaq 0.83% By Medha Singh and Devik Jain. U.S. stock index futures rose on Tuesday after a better-than-expected quarterly profit from IBM (IBM) and on hopes for more domestic stimulus to prop up an economy reeling from the COVID-19 pandemic.

  9. Show article details.

    CBD Offers Cigarette Smokers a New Way Out

    PR Newswire – 9:00 AM ET 07/20/2020

    NEW YORK, July 20, 2020  Tobacco and nicotine addictions are still a major healthcare issues around the globe.

  10. Show article details.

    PMI Launches “Our World Is Not an Ashtray” Initiative and Aims to Halve Plastic Litter from Products by 2025

    Business Wire – 10:13 AM ET 07/16/2020

    New study reveals that one quarter of adult smokers think throwing cigarette butts on the ground is “normal,” confirming cleanup partner Litterati’s belief that education is key Philip Morris International Inc. (PM) today launched “Our World Is Not an Ashtray,” a new global initiative to raise awareness and drive a long-term change in behavior and attitudes around cigarette butt littering.

  11. Show article details.

    Philip Morris International Inc. to Host Webcast of 2020 Second-Quarter Results

    Business Wire – 11:43 AM ET 07/14/2020

    Regulatory News: Philip Morris International Inc. (PM) will host a live audio webcast at www.pmi.com/2020Q2earnings on Tuesday, July 21, 2020, at 9:00 a.m. ET to discuss its 2020 Second-Quarter results, which will be issued at approximately 7:00 a.m. ET the same day.

  12. Show article details.

    Canada's Medicago begins human trials of plant-based COVID-19 vaccine

    Reuters – 8:00 AM ET 07/14/2020

    Medicago said on Tuesday it has begun testing its plant-based coronavirus vaccine in an early-stage clinical trial as the Canadian company, backed by tobacco company Phillip Morris, races against larger drugmakers to develop a treatment option to battle the COVID-19 pandemic.

  13. Show article details.

    PRESS DIGEST-British Business - July 8

    Reuters – 8:53 PM ET 07/07/2020

    The following are the top stories on the business pages of British newspapers. The Times. - British broadcasters ITV, Channel 4 and Sky have called on ministers to introduce new laws "as a matter of urgency" to stem the spread of disinformation on Facebook Inc (FB) and Alphabet Inc's Google. https://bit.ly/3eg6ANb.

  14. Show article details.

    FDA Authorizes Marketing of IQOS as a Modified Risk Tobacco Product

    Business Wire – 2:47 PM ET 07/07/2020

    Regulatory News: The U.S. Food and Drug Administration today authorized the marketing of IQOS, Philip Morris International’s electrically heated tobacco system, as a modified risk tobacco product. - Today’s decision demonstrates that IQOS is a fundamentally different tobacco product and a better choice for adults who would otherwise continue smoking.

  15. Show article details.

    BRIEF-FDA Authorizes Marketing Of IQOS Tobacco Heating System With 'Reduced Exposure' Information

    Reuters – 11:17 AM ET 07/07/2020

    U.S. FDA. * FDA AUTHORIZES MARKETING OF IQOS TOBACCO HEATING SYSTEM WITH 'REDUCED EXPOSURE' INFORMATION. * FDA - AUTHORIZED THE MARKETING OF PHILIP MORRIS PRODUCTS S.A.’S “IQOS TOBACCO HEATING SYSTEM” AS MODIFIED RISK TOBACCO PRODUCTS. * FDA - AUTHORIZATION REQUIRES PHILIP MORRIS PRODUCTS S.A. TO CONDUCT POSTMARKET SURVEILLANCE.

  16. Show article details.

    GSK to develop plant-based COVID-19 vaccine with Canada's Medicago

    Reuters – 10:48 AM ET 07/07/2020

    * GSK has at least seven other partnerships for its adjuvant. * Philip Morris-backed venture uses plant leaves as bioreactors. * Aim is to make 100 million vaccines available by end-2021.

  17. Show article details.

    GSK to develop plant-based COVID-19 vaccine with Canada's Medicago

    Reuters – 8:59 AM ET 07/07/2020

    - The world's largest vaccine-maker GSK has put its vaccine booster technology to work in a potential new COVID-19 shot, to be developed with a Canadian biopharmaceutical company backed by tobacco company Philip Morris (PM) . Rather than developing its own vaccine in the global race to combat the pandemic, GSK has instead focused on contributing its adjuvant technology to at least seve...

  18. Show article details.

    GSK, Philip Morris venture tie-up for potential COVID-19 shot

    Reuters – 8:55 AM ET 07/07/2020

    GSK, the world's largest vaccine maker, on Tuesday announced the latest partnership for its vaccine booster technology to develop and test a potential COVID-19 shot with Canadian biopharmaceutical firm Medicago.

  19. Show article details.

    GSK to work on potential COVID-19 shot with Canada's Medicago

    Reuters – 8:28 AM ET 07/07/2020

    Britain's GSK said on Tuesday it will develop and test a potential COVID-19 vaccine using its booster technology and Canadian biopharmaceutical firm Medicago's coronavirus-like particles. GSK, the world's largest vaccine maker, said the companies aim to make their vaccine available in the first half of next year and produce about 100 million doses by the end of 2021.

  20. Show article details.

    BRIEF-GSK And Medicago To Collaborate On Developing Novel Adjuvanted Covid-19 Candidate Vaccine

    Reuters – 8:09 AM ET 07/07/2020

    GlaxoSmithKline PLC (GSK): * GSK AND MEDICAGO ANNOUNCE COLLABORATION TO DEVELOP A NOVEL ADJUVANTED COVID-19 CANDIDATE VACCINE. * COLLABORATION COMBINES INNOVATIVE PLANT-BASED AND ADJUVANT TECHNOLOGIES TO DEVELOP AND PRODUCE A COVID-19 CANDIDATE VACCINE. * PHASE 1 CLINICAL TESTING SCHEDULED TO BEGIN MID-JULY. * COLLABORATION TO EXPLORE VACCINE DEVELOPMENT OPPORTUNITIES FOR OTHER INFECTIOUS DISEASES.

Page:

Today's and Upcoming Events

  • Oct
    20

    PM to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Jul
    21

    PM announced Q2 earnings.

  • Jun
    19

    PM ex-Dividend for $1.17 on 06/19/2020

    • Announce Date: 06/05/2020
    • Record Date: 06/22/2020
    • Pay Date: 07/10/2020
Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.